Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1135265 | 0.88 | PDE4B (0.51) | PDE4BKLK1KLK5 | |
| SCHEMBL13111069 | 0.83 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DKLK1 | |
| SCHEMBL3472805 | 0.81 | PDE4B (0.57) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13637188 | 0.80 | CA12 (0.57) | CA12CA1CA2CA9PDE4B | |
| SCHEMBL22847887 | 0.79 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3475972 | 0.79 | CA12 (0.59) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3472670 | 0.78 | PDE4B (0.60) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13637220 | 0.78 | KLK1 (0.51) | PDE4BPDE4CPDE4DKLK1KLK5 | |
| SCHEMBL13111041 | 0.77 | PDE4B (0.57) | PDE4BPDE4APDE4CPDE4DKLK1 | |
| SCHEMBL3474688 | 0.76 | PDE4A (0.80) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2009140309-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | CA12 564/4885CA1 4452/4885CA2 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.